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Summary The blocking of angiogenesis provides a novel therapeutic target to inhibit tumour spreading. In this study, we investigated the
effect of linomide on angiogenesis induced in vivo by highly angiogenic breast carcinoma cells. The rabbit cornea was used to assess
neovascular growth in the absence of a tumour mass. MCF-7 cells stably transfected with the cDNA encoding forvascular endothelial growth
factor 121 (VEGF121) (V12 clone) were used to elicit a potent VEGF-dependent corneal angiogenesis. After tumour cell implant, albino rabbits
received 100 mg kg-1 day-1 linomide for 5 consecutive days. Daily observation of neovascular progression indicated that linomide blocked
angiogenesis. The antiangiogenic effect of linomide was apparent within 48 h from the beginning of the treatment and was both
angiosuppressive and angiostatic. The block of neovascular growth lasted over 10 days from treatment suspension, and preformed vessels,
which had regressed, remained dormant, suggesting the persistence of unfavourable conditions for capillary progression. Linomide (50-
200gg ml-1) was not cytotoxic in vitro on resting capillary endothelial cells but blocked endothelial cell replication induced by VEGF. Our data
indicate that linomide can efficiently and persistently block VEGF-dependent angiogenesis in vivo in the absence of a growing tumour mass.
These data suggest that linomide could be a chemopreventive drug in breast cancer patients and a valuable tool in clinical settings in which
metastatic spreading occurs in the absence of a detectable tumour mass.
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There is compelling experimental evidence that angiogenesis is
necessary for tumour growth and spreading. Clinicopathological
studies have shown that this can be translated in human tumours,
such as breast cancer (Horak et al, 1992; Weidner et al, 1992; Toi
et al, 1993: Gasparini et al, 1994; Gasparini and Harris, 1995). In
the metastatic cascade angiogenesis is implicated both in the stage
ofshedding from a primary tumour and upon arrival ofmetastases
at their distant site (Folkman, 1995). Based on these observations,
antiangiogenic therapy has been proposed as adjuvant therapy in
solid primary tumours to prevent invasion and metastasis (Fan et
al, 1995; Folkman, 1995).
Vascular endothelial growth factor (VEGF) appears to play a
key role in tumour angiogenesis (Brown et al, 1993; Klagsbrun
and Soker, 1993; O'Brien et al, 1995). In breast cancer, the expres-
sion and levels (Toi et al, 1996; Gasparini et al, 1997) of VEGF
correlate with high microvessel density, and both features are
associated with poor prognosis. Thus, breast cancer with high
microvessel density and/or VEGF expression may be a likely
candidate for antiangiogenic treatment.
Transfection of VEGF121 into the human breast carcinoma cell
line (MCF-7 cells) has been previously shown to enhance tumour
growth and vascular density in vivo and to promote a strong angio-
genic response (Zhang et al, 1995). VEGF121 transfectants (V12
cells) thus provide a useful model for monitoring the antiangio-
genesis effect ofspecific inhibitors.
The quinoline-3-carboxamide linomide has been reported to
have immunomodulatory activity (Kalland et al, 1985; Larsson et
Received 16 May 1997
Revised 15 September 1997
Accepted 16 September 1997
Correspondence to: M Ziche
al, 1987; Bengtsson et al, 1992) and to block angiogenesis effi-
ciently in experimental tumour models (Kalland, 1986; Harning et
al, 1989; Ichikawa et al, 1992; Vukanovic et al, 1993; Joseph et al,
1996). Moreover, we recently demonstrated the ability oflinomide
to selectively inhibit VEGF-induced migration and growth of
microvascular endothelium (Parenti et al, 1996; Ziche et al,
1997a), indicating that the drug could target the inhibition of
VEGF-dependent tumour angiogenesis in vivo.
The cornea is an ideal model for monitoring the occurrence of
angiogenesis as it allows the direct observation of vascular
progression over time. By using wild-type MCF-7 and VEGF121
transfectants, the aim ofthis study was to assess in vivo the effect
of linomide on the angiogenesis induced by breast carcinoma cell
populations. The effect of drug treatment was assessed on angio-
genesis that had already been established by the tumour cells as
well as before neovascular growth had become apparent, two
experimental settings that mimic the clinical conditions in which
tumour angiogenesis contributes to tumour progression and
spreading. The effect of linomide on tumour and endothelial cell
growth has also been investigated.
MATERIALS AND METHODS
Angiogenesis in vivo: rabbit cornea assay
Angiogenesis was studied in the cornea ofalbino rabbits, as this is
an avascular and transparent tissue in which inflammatory reac-
tions and growing capillaries can be easily monitored and the
modification can be quantitated by stereomicroscopic examina-
tion. Female New Zealand white rabbits (2.5-3 kg, Charles River,
Calco, Como, Italy) were used in accordance with the guidelines
of the European Economic Community for animal care and
welfare (EEC law no. 86/609). In animals anaesthetized by sodium
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pentothal (30 mg kg-'), a micropocket (1.5x3 mm) was surgically
produced using a pliable iris spatula 1.5 mm wide in the lower half
of the rabbit eye. Approximately 2.5x105 wild-type MCF-7 cells
(WT) or VI2 transfectants as a cell suspension in a 10-,l volume
were implanted in the micropocket following a procedure
previously reported (Ziche and Gullino, 1982). Subsequent daily
observations of the implants were made with a slit lamp stereo-
microscope. An angiogenic response was scored positive when
budding of vessels from the limbal plexus occurred after 48 h and
capillaries progressed to reach the implant according to the
scheme previously reported (Ziche et al, 1989). The number of
positive implants over the total implants performed was scored
during each observation.
The potency of angiogenic activity was evaluated on the basis
ofthe number and growth rate ofnewly formed capillaries, and an
angiogenic score was calculated (vessel density x distance from
limbus) (Ziche et al, 1997b). A density value of 1 corresponded to
0-25 vessels, 2 from 25 to 50, 3 from 50 to 75, 4 from 75 to 100, 5
from 100 to 200 and 6 for more than 200 vessels. The distance
(mm) from the limbus was graded with the aid of an ocular grid.
Corneas were removed at the end of the experiment as well as at
a defined interval from surgery and/or treatment and fixed in
formalin for histological examination.
Linomide treatment
Linomide was kindly provided by Dr Beryl Hartley-Asp of Kabi
Pharmacia Therapeutics, Lund, Sweden. The dry powder was
solubilized in water to obtain a concentration of200 mg ml. This
volume of solution was calculated to provide the required amount
in 1-1.5 ml for i.v. injection. After solubilization, the compound
was stored at 4°C. To assess the effect of the compound as a
blocker of neovascular growth, linomide was administered by i.v.
injections at the dose of 100 mg kg-1 day-1 for 5 consecutive days.
The treatment was given 24 h after the surgical implant of the
cells, i.e. before any angiogenesis had occurred. To assess the
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Figure 1 In vivo angiogenesis by wild-type human breast carcinoma cell
line MCF-7 (WT) (O) and VEGF transfectants (V12) (-). Data are expressed
as the angiogenic score calculated by vessel density x vessel length as
described in Materials and methods
effect of linomide once angiogenesis had been induced by tumour
cells, the drug was given to the rabbits at the same dosage and
schedule as above, starting fromday 7 after the implant ofthe cells
in the cornea.
Control animals received an equal volume (1 ml) of saline
buffer solution following the same schedule ofadministration.
Cell lines and culture conditions
Low passages of the human breast carcinoma cell line MCF-7
(wild type, WT) and the VEGF21-transfected MCF-7 cells (clone
V12) (Zhang et al, 1995) were provided by Dr Roy Bicknell,
Imperial Cancer Research Fund, University of Oxford, Oxford,
UK. The cell lines were kept in culture in Dulbecco's modified
Eagle medium (DMEM) with 4500 mg of glucose per 1 supple-
mented with 10% fetal calf serum (FCS). V12 transfectants,
selected forneomycin resistance, were maintained in culture in the
presence ofthe antibiotic G418 (500 ,ug ml-').
Post-capillary endothelial cells (CVECs) were obtained by a
bead perfusion technique of the bovine coronary sinus (Schelling
et al, 1988) and were a gift from Dr Harris J Granger, Micro-
circulation Research Institute and Department of Medical Physi-
ology, Texas A&M University, College Station, USA. Cells were
maintained in culture in DMEM supplemented with antibiotics
and 10% FCS on gelatin-coated dishes. Subclones growing un-
modified formorphological appearance andbiological response to
the angiogenesis factors up to 28 passages were selected and cells
between passage 12 and 18 were used in these experiments.
Proliferation assay
Cell growth was quantified by the total cell number recovered
after exposure to test substances as previously reported (Ziche
et al, 1997b). Experiments were performed using DMEM supple-
mented with 10% FCS for tumour cells and 1% FCS for CVEC.
Cells (3x103 per 500p1) suspended in 5% FCS medium were
seeded in 48 multiwell plates. After incubation with test
substances (2 days for CVEC and 4 days for WT and V12 cells),
cells were fixed with 100% methanol overnight at 4°C and stained
with Diff-Quik (Mertz+Dade AG, Dudingen, Switzerland). The
number of cells was counted under blind conditions in seven
random fields of each well at a magnification of 200 with the aid
of an ocular grid. Data (means±s.e.m.) are expressed as the
number ofcells counted per well.
Statistical analysis
Numerical values are expressed as mean ± s.e.m. Statistical
analysis was performed using Student's t-test for paired and/or
unpaired data. A P-value < 0.05 was taken as significant.
RESULTS
Characterization of the angiogenic phenotype of MCF-7
transfectants
The morphogenetic evolution of angiogenesis by MCF-7 overex-
pressing or not overexpressing VEGF was monitored and charac-
terized over time after cell transplantation into the avascular
corneal tissue. The implant of wild-type MCF-7 (WT) did not
induce angiogenesis during the first 10 days of observation, but
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Figure 2 Corneal angiogenesis by wild-type MCF-7 and VEGF transfectants (V12 cells): effect of linomide. Representative pictures ofwild-type MCF-7
(A) and V12 cells (B) after 15 days from the surgical implant in the cornea of albino rabbits. (C) Vascular progression elicited by V12 transfectants 7 days after
implant in the rabbit cornea. At this stage of angiogenesis, systemic linomide treatment (i.v. 100 mg kg-' day-') given to the animals for 5 consecutive days
strongly suppressed corneal neovascularization. (D) V12 transfectants, day 15 post implant, compared with control untreated animal in B
prompted a detectable neovascular response 2 weeks after
transplantation (Figure 1 and Figure 2A). Conversely, VEGF-
expressing cells (V12) rapidly elicited the appearance of a strong
angiogenic response (Figure 2B). Within 3 days from surgical
implant, a consistent number of capillaries had grown from the
limbus and after 1 week angiogenesis had progressed over 1 mm
into the avascular cornea (Figures 1 and 2C). The area of corneal
vascularization induced at day 10 was between 6 and 10 mm2 for
V12 clone cells and between 2 and 4 mm2 for WT cells.
Linomide is angiostatic and angiosuppressive on
vascularization induced by VEGF transfectants
In a general clinical situation, tumours are vascularized and angio-
genesis is present at the site of tumour diffusion and spreading.
Thus, this type of neovascularization is presumably present at the
time of tumour detection and removal and is a likely target of the
antiangiogenic treatment to prevent metastases. To mimic this
condition, linomide was given at the time when V12 cells had
elicited a consistent number of capillaries to travel about 1 mm
from the limbus and to actively grow into the corneal stroma
(Figure 2C). Treatment started at day 7 from the cell implant into
the rabbit cornea and was given for the following 5 days. After 2
days of treatment, the number and the growth rate of the newly
formed capillaries was only slightly different between the treated
animals and the controls. In the following observations, however,
the advancement of the capillary front into the corneal stroma was
consistently repressed in treated animals compared with the
controls (Figure 3A). The progression of growing capillaries
(length) appeared to be blocked (Figure 3B). Involution of the
preformedcapillaries occurred, leading to a reduction in the density
of the vessels (Figures 2D and 3C). Despite discontinuation of the
treatment, the angiostatic/angiosuppressive effect of linomide
persisted and a consistent reduction of angiogenesis was still
present after 7 days from the end oftreatment (data not shown).
Treatment with linomide prevents the occurrence of
neoangiogenesis
To assess the effect of linomide in a model of tumour cells in a
prevascular stage, animals were treated for 5 consecutive days
24 h after the corneal implant of VI2 cells and before any angio-
genesis occurred. The number and growth rate of neovessels
(density) and their ability to invade and progress into the avascular
cornea (length) were reduced compared with untreated rabbits
(Figure 4). Four days after the implant (3 days of treatment),
treated animals had only few buds sprouting from the limbal
vessels, while in the control group a dense network of capillary
outgrowth had progressed approximately 0.7 mm (23%) from the
limbus. The angiosuppressive effect was still present after 10 days
from the discontinuation of the treatment (Figure 4) and persisted
up to the third week of observation (data not shown). In the
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Figure 3 Effect of linomide on established vascularization. Linomide treatment (i.v. 100 mg kg-1 day-') was initiated 7 days post implant of VEGF transfectants
(Vl2 cells) into the corneal stroma and was given for 5 consecutive days. O, Control untreated animals; *, linomide-treated animals. (A) Angiogenesis is
expressed by the angiogenic score as in Figure 1. (B) Vessel length and (C) vessel density are plotted over time. Data are means ± s.e.m. of measures
obtained from seven animals for each group
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Figure 4 Effect of linomide on new vessel formation. VEGF transfectants (Vi2 cells) were implanted into the corneal stroma, and linomide (i.v. 100 mg kg-1
day-') was given to the animals 24 h later for 5 consecutive days. L, Control untreated animals; *, linomide-treated animals. (A) Angiogenesis is expressed by
the angiogenic score as in Figure 1. (B) Vessel length and (C) vessel density are plotted over time. Data are means ± s.e.m. of measures obtained from seven
animals for each group
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Figure 5 Effect of linomide on angiogenesis induced by wild-type MCF-7
cells. MCF-7 cells were implanted into the corneal stroma, and linomide
(i.v. 100 mg kg-' day-') was given 24 h later for 5 consecutive days. In control
untreated animals (E) angiogenesis appeared at 14 days; at this time
linomide (O) was able to reduce the neovascular growth induced by MCF-7
cells. Data are expressed as the angiogenic score as in Figure 1. Data are
means ± s.e.m. of measures obtained from five animals for each group
Table 1 Effect of linomide on the proliferation of tumour and endothelial
cells
Counted cells per well
Control +Linomide +Linomide +Linomide
50jg ml-, 100 ,ug ml-' 200 ,ug ml-'
WT 245 ± 5 ND 274 ± 12 211 ± 19
V12 222±4 ND 216±5 228±10
CVEC
Basal 40 + 3 40± 1.7 46± 1.1 30± 0.5
VEGF 58± 1.7 34 ± 2.5** 42 ±2** 34± 0.5**
bFGF 59±2 42±3.2* 45±2.1 42±4.2*
Proliferation was quantified by the number of cells recovered after 2 days
and 4 days of exposure to test substances for CVEC and WTN12 cells
respectively. To evaluate the effect of linomide on endothelial cell
proliferation, cells were pretreated with the appropriate concentration of the
agent 2 h before VEGF and bFGF were added. Data are expressed as total
cells counted per well in seven random fields at a magnification of 200. Data
represent mean ± s.e.m. of three experiments run in triplicate. *P< 0.01 and
**P< 0.001 vs bFGF and VEGF alone respectively. ND, not done.
absence of VEGF transfection, MCF-7 elicited a delayed angio-
genesis, suggesting a dormant phenotype for angiogenesis (Figure
1). The administration of linomide in this experimental condition
further delayed the occurrence ofangiogenesis (Figure 5).
Effect of linomide on tumour and endothelial cell
growth in vitro
The possibility that the antiangiogenic effect oflinomide could be
linked to a direct cytotoxic effect on tumour cell growth was ruled
out by exposing the cells in culture to the compound. As shown in
Table 1, we found that the growth pattern of WT and V12 cells
exposed for 4 days to 100 and 200 ,ug ml-1 linomide was not
modified by the agent.
Linomide was then assessed on the growth of post-capillary
endothelial cells (CVEC). Linomide at 50 and 100 ,ug ml' did
not affect endothelial cell proliferation, while at 200 ,ug ml-l it
slightly reduced the spontaneous replication of serum-deprived
cells. When CVEC were stimulated to grow with either VEGF
(20 ng ml') or bFGF (10 ng ml-'), linomide abolished theprolifer-
ation induced by either growth factor (Table 1). Interestingly,
VEGF-treated cells were more sensitive to linomide inhibition.
DISCUSSION
This study documents for the first time that linomide exerts a
specific antiangiogenic effect in vivo on breast tumour cells and
efficiently blocks capillary growth elicited by VEGF breast cancer
transfectants. The results of our study demonstrate by continuous
and direct monitoring of the capillary sprouting in vivo that
linomide prevents and blocks the angiogenesis elicited by breast
carcinoma cells by modifying endothelial cell responsiveness to
the angiogenic trigger. These observations are substantiated by in
vitro studies showing that microvascular endothelium treated with
linomide does not proliferate in response to VEGF.
Angiogenesis and VEGF expression are correlated with poor
prognosis in breast cancer patients. Among the angiogenic factors
produced by tumours, VEGF seems to be the predominant angio-
genic factor expressed in primary breast carcinoma and appears to
play a key role in pathological angiogenesis (Toi et al, 1996;
Gasparini et al, 1997). Linomide has been reported to reduce the
growth ofprostatic tumours by modifying the immune response of
the host (Ichikawa et al, 1992), by cytokine production (Vukanovic
and Isaacs, 1995) and by inducing vascular alterations within
the tumour, leading to angio-inhibition (Vukanovic et al, 1993;
Vukanovic and Isaacs, 1995). Moreover, linomide has been shown
to inhibit mammary carcinogenesis in rodents and to block vas-
cular proliferation induced in matrigel (Joseph et al, 1996). Based
on these considerations, our aim was to assess whether linomide
could be an efficient antiangiogenic drug for breast cancer and
whether it could antagonize a specific endothelial mitogen respon-
sible for tumour angiogenesis. The MCF-7 transfectants are an
appropriate model to reproduce a highly angiogenic phenotype of
a tumour cell population linked to VEGF overexpression. The
transplant of tumour cells into the avascular cornea of albino
rabbits allows the assessment of the morphogenetic evolution of
angiogenesis during time and the comparison in the same animal
ofcell populations with distinct angiogenic phenotypes (Ziche and
Gullino, 1982). More importantly, the effect of drug treatment
on angiogenesis can be evaluated in each animal during time,
independently of tumour growth, thus allowing an accurate and
specific monitoring ofthe antiangiogenic effect. Two experimental
protocols were designed to mimic the clinical situations that an
antiangiogenic treatment should target: the neovascularization
already established by the tumour at the time of detection and the
occurrence of angiogenesis linked to metastasis spreading and
growth. Our results indicate that linomide is able to affect the early
steps of new vessel formation, resulting in suppression of the
angiogenesis elicited by highly angiogenic tumour cell popula-
tions and further delaying the occurrence of angiogenesis of
tumour cells with a dormant angiogenic profile. Linomide given to
the animals before frank angiogenesis was produced, leads to a
long-lasting angio-inhibition. Consistently, once florid angiogen-
esis has been established by the VEGF transfectants, the treatment
blocks the neovascular progression and results in the involution of
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the corneal vascularization. The effects of linomide are thus both
angiostatic and angiosuppressive. In keeping with the finding that
a specific inhibitor ofangiogenesis does not directly interfere with
the growth oftumour cells in vitro (Ichikawa et al, 1992; Yamaoka
et al, 1993), we found that linomide does not affect the growth
pattern of either MCF-7 or V12 cells in vitro.
In a previous study, linomide was reported to block in vitro the
long-term replication of the endothelium without cytotoxicity
(Vukanovic et al, 1993). We recently reported the ability of lino-
mide to selectively target VEGF-induced endothelial cell migration
(Parenti et al, 1996; Ziche et al, 1997a). Consistently in the present
study we document that the drug efficiently impairs endothelial cell
replication promoted by VEGF, substantiating that linomide can
specifically counteract the effect of VEGF on angiogenesis.
In patients with breast carcinoma, there is evidence that angio-
genesis plays a role in primary tumour progression (Brem et al,
1977; Zajchowski et al, 1990) and in the development of metas-
tasis (Gasparini and Harris, 1995). Breast cancer patients with
highly vascularized tumours have poor outcome even if treated
with conventional adjuvant chemotherapy or hormone therapy
(Gasparini et al, 1995). Several reports show that there exists a
significant association between intratumoral microvessel density
and the expression and levels of VEGF in primary invasive breast
carcinomas and that VEGF is the most important angiogenic
peptide in this neoplasm (Toi et al, 1996; Gasparini et al, 1997).
These observations indicate that breast cancer patients are likely to
benefit from antiangiogenic treatment and emphasize that knowl-
edge ofthe specific mechanisms ofthe antiangiogenic intervention
are needed for a rational therapeutic approach based on the
modulation ofangiogenesis.
In conclusion, linomide appears to be a promising antiangio-
genic inhibitor that should be tested in patients with breast cancer
as a new anti-cancer therapeutic strategy. Recent evidence
suggests that, in spite of the redundancy of angiogenic factors
potentially involved in pathological angiogenesis, strategies aimed
at antagonizing one specific endothelial cell mitogen may form the
basis for an effective and safe treatment of cancer and metastases.
Patients with primary tumours with high microvessel density and
with high VEGF expression are likely to obtain the highest benefit
from angiogenesis inhibition with linomide given alone or in
combination with conventional adjuvant anti-cancer treatments, in
accordance with the approach of Teicher et al (1992), which
involves the targeting oftwo-cell compartments.
ABBREVIATIONS
VEGF, vascular endothelial growth factor; bFGF, basic fibroblast
growth factor; CVEC, coronary venular endothelial cells; MCF-7,
human breast carcinoma cell line; WT, wild type; V12, VEGF121
transfectant clone; DMEM, Dulbecco's modified Eagle medium;
FCS, fetal calf serum
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